...Haul” ). Three of the four -- Annexon Inc. (NASDAQ:ANNX), Nurix Therapeutics Inc. (NASDAQ:NRIX) and iTeos Therapeutics Inc....
...Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul Bonanos, Associate Editor Annexon Inc. iTeos Therapeutics S.A. Nurix Therapeutics Inc. Inozyme Pharma Inc. 4D Molecular Therapeutics Inc. AlloVir iTeos Therapeutics Inc....

...Several more companies in the queue proposed terms for their listings, including Annexon Inc., iTeos Therapeutics Inc....
...Inc. and Inozyme Pharma Inc. Paul Bonanos, Associate Editor Everest Medicines Ltd. Freeline Therapeutics Ltd. Checkmate Pharmaceuticals Inc. Annexon Biosciences Inc. iTeos Therapeutics...

...public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc. and iTeos Therapeutics...
...TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos Therapeutics...

...health systems at Alkermes plc (NASDAQ:ALKS). Robin Sawka, BioCentury Staff Constellation Pharmaceuticals Inc. Inspire Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics...

...after PD-1 that’s been validated with that kind of data,” said Joanne Lager, CMO of iTeos Therapeutics...

...chemokine receptor 8 TIGIT - T cell immunoreceptor with Ig and ITIM domains Paul Bonanos, Associate Editor EOS100850 EOS884448 iTeos Therapeutics...

...is VP and head of the U.S. immunology, hepatology & dermatology franchise. Cancer immunotherapy company iTeos Therapeutics...
...genomics and the Genetics Research Center of Excellence at AbbVie Inc. (NYSE:ABBV). Hongjiang Li, Staff Writer Biodesix Inc. iTeos Therapeutics...

...LLP, Merck Ventures, IP Group plc (LSE:IPO), AbbVie Ventures Products targeting DNA damage repair Cancer iTeos Therapeutics...

...of an undisclosed new biotech company. The cancer company is seeking a successor. Immunotherapy company iTeos Therapeutics...
...VP at 6 Dimensions Capital. BioCentury Staff Abingworth Aprea Therapeutics AB Arcus Biosciences Inc. CytomX Therapeutics Inc. Forma Therapeutics Inc. Intra-Cellular Therapies Inc. iTeos Therapeutics...

...Therapeutics Inc. in December and led a $75 million series B round for immunotherapy play iTeos Therapeutics...